We support the development of cutting-edge cell therapies, offering comprehensive services from vector design and cell engineering to in vitro efficacy and safety testing. Our advanced 3D Cell Platforms and Immune Cell Platforms enable precise and effective development of cell therapies.
With unparalleled expertise in immune cell therapies and cutting-edge analytics, we are your trusted partner for advancing immune cell therapy projects across all formats, including CAR-T, TCR-T, CAR-NK, CAR-γδ T, and CAR-Macrophages.
We deliver tailored solutions, leveraging the latest innovations and industry best practices in:
Construct design
Cell Engineering and Expansion Optimisation
Efficacy
Safety
Characterisation
By utilising cutting-edge molecular biology, we can guide you through construct design, tailored to your specific needs. With extensive experience in both conventional CAR and TCR designs and advanced structures like conditional, bispecific, dual, and logic-gated CARs, we ensure your project’s success. Our expertise spans viral and non-viral vector delivery methods, and we use advanced technologies like CRISPR (MAD7) for precise genetic modifications. We understand immune cell biology, integrating this knowledge into construct design to maximise efficacy and safety.
Developing effective CAR cell therapies demands precise immune cell engineering methodologies to enhance therapeutic potential. We have extensive expertise in genetic modification, expansion, and differentiation of diverse immune cells, including αβ and γδ T cells, natural Tregs, TILs, NK cells, and macrophages. We specialise in both viral and non-viral methods, such as transposons and RNA, offering custom solutions tailored to your project. Our expansion strategies are designed to optimise activation, transduction, and growth conditions, ensuring the final product meets your desired functional characteristics.
We offer a range of assay systems and tools to assess on-target efficacy and Mechanism of Action (MOA) of immune cell therapies and can develop custom solutions to support unique development requirements. The extended portfolio of assay systems and tools include:
Evaluating the safety and efficacy of CAR cell therapies involves extensive in vitro and in vivo testing. This includes assessing the potential for on-target, off-tumour toxicity, Cytokine Release Syndrome (CRS), immunogenic potential and cytokine-independent proliferation.
Immune cell products are complex and heterogeneous and require extensive characterisation to ensure safety and potency characteristics. At Rouken Bio we employ flow cytometry or single cell RNA sequencing (scRNA-seq) to provide unparallel, in-depth characterisation of the cell therapy product.
Connect with us today to explore how our expertise can drive the success of your immune cell therapy project. Let’s transform innovative ideas into impactful therapies together.
Difficulty doesn’t deter us; it inspires us. Give us a problem, and we’ll find your solution. Our versatile specialists embrace every obstacle as an opportunity to showcase our innovative thinking and problem-solving prowess.
BOOK A MEETING